1020 - 1135 GMT+9
Monday 30 August
Morning Symposium 6
Filgotinib, new JAK Inhibitor: Applications and Perspectives in Rheumatoid Arthritis
Filgotinib, a highly-balanced JAK1 inhibitor, had been approved for the indication of ” Rheumatoid arthritis in patients who had an inadequate response to conventional therapies (including prevention of structural damage to joints)” in Japan and has been commercialized since November 2020.In this symposium, characteristics and features of filgotinib will be reviewed; safety and efficacy profiles of filgotinib examined in the global phase III studies FINCH-1 (MTX-IR), FINCH-2 (bDMARDs-IR), and FINCH-3 (MTX-naïve) focusing on Asian / Japanese subpopulations in comparison with overall subjects. We will also review stratified analyses data of each study above to differentiate from other JAK inhibitors.We would also like to comprehensively review safety concerns especially for herpes zoster, which is to be cautious in Asian /Japanese populations, and to discuss clinical significance and future expectations of filgotinib.
Chair: Emeritus Prof Tsutomu Takeuchi, Keio University, Japan

Filgotinib, new JAK Inhibitor: Applications and Perspectives in Rheumatoid Arthritis
Prof Hideto Kameda
Toho University, Japan